厦门特宝生物工程股份有限公司 关于参加科创板 2023 年度集体业绩说明会 第三期"提质增效重回报"专场的公告 证券代码：688278 证券简称：特宝生物 公告编号：2024-020 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2024 年 5 月 14 日（星期二）16:00 前过邮件、电话、传真等 形式将需要了解和关注的问题提前提供给公司。公司将在文字互动环节对投资者 普遍关注的问题进行回答。 厦门特宝生物工程股份有限公司（以下简称"公司"）已于 2024 年 3 月 29 日发布公司 2023 年度报告，为便于广大投资者更全面深入地了解公司 2023 年经 营成果、财务状况、发展理念等事项，公司参与科创板 2023 年度集体业绩说明 会第三期"提质增效重回报"专场，重点交流提质增效重回报的相关举措。此次 活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所上证 路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资 ...

证券代码：688278 证券简称：特宝生物 公告编号：2024-019 厦门特宝生物工程股份有限公司 关于派格宾增加适应症拟纳入优先审评程序的 自愿性披露公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）药品派格宾联合核 苷（酸）类似物适用于临床治愈成人慢性乙型肝炎的增加适应症（以下简称 "增加适应症"）的上市许可申请近日被国家药品监督管理局药品审评中心纳 入拟优先审评品种公示名单，公示期为 2024 年 5 月 7 日至 2024 年 5 月 13 日。 现将相关情况公告如下： 一、药品基本情况 药品名称：派格宾® 通用名称：聚乙二醇干扰素 α-2b 注射液 申请人：厦门特宝生物工程股份有限公司 拟定适应症（或功能主治）：派格宾联合核苷（酸）类似物适用于临床治 愈成人慢性乙型肝炎。 拟优先评审理由：本品符合《药品注册管理办法（国家市场监督管理总局 令 2020 年第 27 号）》和《国家药监局关于发布<突破性治疗药物审评工作程 序（试行）>等三个文件的公告》（2020 年 ...

\\\\\\\\\\\ 业绩简评 2024 年 4月 22 日，公司发布2024 年第一季度报告，2024年第一 季度公司实现收入5.45 亿元，同比增长30.05%；实现归母净利润 1.29 亿元，同比增长 53.03%；实现扣非归母净利润 1.46 亿元， 同比增长42.90%。2024 年一季度公司经营活动产生的现金流量净 额为 0.79 亿，同比增长260.06%。 经营分析 乙肝治愈临床证据不断积累，派格宾持续快速放量。公司开展的 以临床治愈为治疗目标的确证性临床试验按计划推进，派格宾联 合核苷（酸）类似物适用于临床治愈成人慢性乙型肝炎的增加适应 症的上市许可申请于2024 年 3月获得国家药监局受理。公司持续 支持了包括“珠峰”、“绿洲”、“未名”、“萌芽”、“星光”、“领航” 等多项乙肝临床治愈及肝癌预防公益及科研项目，在各相关机构 人民币(元) 成交金额(百万元) 的紧密合作与共同努力下各个项目稳步推进，部分项目阶段性成 73.00 450 果陆续在亚太肝病研究学会（APASL）、欧洲肝脏研究学会（EASL）、 66.00 400 350 美国肝病研究学会（AASLD）年会发布，进一步证实乙肝 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥545,302,286.89, representing a year-over-year increase of 30.05%[4] - Net profit attributable to shareholders for Q1 2024 was ¥128,807,591.33, reflecting a growth of 53.03% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥146,409,781.65, an increase of 42.90% year-over-year[4] - Basic earnings per share for Q1 2024 was ¥0.32, up by 52.38% from the same period last year[4] - Total operating revenue for Q1 2024 reached ¥545,302,286.89, an increase of 30.1% compared to ¥419,307,024.70 in Q1 2023[19] - Net profit for Q1 2024 was ¥128,807,591.33, representing a 52.9% increase from ¥84,173,127.64 in Q1 2023[20] - Earnings per share for Q1 2024 were ¥0.32, compared to ¥0.21 in Q1 2023, reflecting a 52.4% increase[21] - The company reported a total comprehensive income of ¥128,807,591.33 for Q1 2024, compared to ¥84,173,127.64 in Q1 2023, marking a 52.9% increase[21] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥78,663,848.24, showing a significant increase of 260.06%[4] - In Q1 2024, the company generated operating cash inflow of ¥628,928,052.33, a significant increase from ¥387,126,178.14 in Q1 2023, representing a growth of approximately 62.3%[22] - The net cash flow from operating activities for Q1 2024 was ¥78,663,848.24, compared to ¥21,847,454.23 in Q1 2023, indicating a year-over-year increase of about 259.5%[23] - The company reported cash outflow from operating activities totaling ¥550,264,204.09 in Q1 2024, up from ¥365,278,723.91 in Q1 2023, reflecting a rise of approximately 50.6%[23] - The company’s cash and cash equivalents increased by ¥242,422,225.78 in Q1 2024, compared to an increase of ¥219,539,221.52 in Q1 2023, indicating a growth of about 10.4%[24] - The ending balance of cash and cash equivalents reached ¥655,073,171.04 in Q1 2024, up from ¥519,870,257.78 in Q1 2023, representing an increase of approximately 26.0%[24] Assets and Liabilities - The company's total assets at the end of Q1 2024 were ¥2,426,913,277.69, a 3.01% increase from the end of the previous year[5] - The company's total assets reached CNY 2.43 billion, up from CNY 2.36 billion in the previous period, indicating a growth of approximately 3.0%[16] - Total liabilities decreased to ¥421,704,343.64 in Q1 2024 from ¥479,685,751.45 in Q1 2023, a reduction of 12.1%[18] - The company's non-current assets totaled CNY 1.09 billion, an increase from CNY 1.02 billion, representing a growth of about 7.5%[16] - The accounts receivable decreased to CNY 394.76 million from CNY 437.81 million, showing a decline of approximately 9.8%[15] Research and Development - R&D investment totaled ¥55,622,956.59, which decreased by 20.66% year-over-year, and accounted for 10.20% of operating revenue, down by 6.52 percentage points[4][5] - Research and development expenses for Q1 2024 were ¥43,575,928.52, an increase of 15.5% from ¥37,712,423.75 in Q1 2023[19] Shareholder Information - The company reported a total of 7,632 shareholders at the end of the reporting period, with the largest shareholder holding 33.94% of the shares[9] - Total equity attributable to shareholders increased to ¥2,005,208,934.05 in Q1 2024, up 6.9% from ¥1,876,401,342.72 in Q1 2023[18] Charitable Contributions - The company donated CNY 8 million to the "China Chronic Hepatitis B Clinical Cure (Everest) Project," with CNY 200,000 donated during the reporting period[13] - The company has committed to donating up to 30,000 doses of Peginterferon to support hepatitis patients, with 10,000 doses already donated[14] - The company has donated CNY 477.4 million to the "Qihang Project" aimed at exploring treatment options for chronic hepatitis B patients[14] - The company has engaged in various charitable donations, totaling CNY 2.56 million in cash donations to various foundations by the end of the reporting period[13] Operating Costs - Total operating costs for Q1 2024 were ¥379,688,432.09, up 24.7% from ¥304,580,777.32 in Q1 2023[19] - Sales expenses rose to ¥241,910,759.84 in Q1 2024, up 30.0% from ¥186,144,235.35 in Q1 2023[19] - The company paid ¥239,962,364.78 in employee compensation in Q1 2024, which is a significant increase from ¥123,793,401.72 in Q1 2023, reflecting a growth of about 93.9%[23] - Tax payments in Q1 2024 amounted to ¥56,272,206.36, compared to ¥24,146,198.04 in Q1 2023, indicating an increase of approximately 133.4%[23] - The company’s cash outflow related to other operating activities was ¥207,741,927.92 in Q1 2024, slightly up from ¥196,536,352.53 in Q1 2023, showing an increase of about 5.4%[23] Product Recognition - The significant increase in operating revenue was attributed to the growing recognition of the product Paigebin among experts and patients, leading to sustained sales growth[8]

厦门特宝生物工程股份有限公司 投资者关系活动记录表 （2023 年度生物制品专场集体业绩说明 公司代码：688278 公司简称：特宝生物 产品没有明显季节性销售特征；2024 年 3 月，派格宾联合核苷 （酸）类似物适用于临床治愈成人慢性乙型肝炎的增加适应症 上市许可申请获得国家药监局受理，后续尚需经过技术审评、 药品注册核查、审批等环节，申请能否获得批准存在不确定 性，公司将根据有关规定及时履行信息披露义务。 三、尊敬的领导，您好，我的问题如下：1、请问在去年的 派格宾销售收入中，有多大比例是走医保的？2、去年全年使用 派格宾治疗的人数同比增加多少？今年第一季度使用派格宾的 人数比去年同期增加多少？3、佩金的销售主要是委托第三方 吗？还是走公司现有的销售渠道？ 答：您好！（1）该数据较难统计。（2）目前派格宾的渗 透率尚未有第三方发布的权威数据，随着科学证据的积累和临 床治愈理念的加深，使用派格宾进行治疗的患者数量正逐步增 加。（3）公司将珮金在中国大陆地区的独家推广及销售权利授 予江苏复星，具体详见公司于 2023 年 6 月 1 日在上海证券交易 所披露的《关于签署独家商业化协议的公告》（公告编号： 2 ...

Group 1: Product Information - The product Paigebin has been included in the National Medical Insurance Directory (Category B) [3] - The reimbursement rate for Paigebin varies by region due to different local medical insurance policies [3] - There is no significant seasonal sales characteristic for Paigebin [4] Group 2: Sales and Market Insights - The proportion of Paigebin sales that go through medical insurance is difficult to quantify [4] - The number of patients using Paigebin is gradually increasing as scientific evidence accumulates [4] - The exclusive promotion and sales rights of Peijin in mainland China have been granted to Jiangsu Fosun [4] Group 3: Future Expectations - The sales expense ratio is expected to continue decreasing as sales scale increases [5] - The company is awaiting approval for the clinical cure indication for chronic hepatitis B, which is currently under review by the National Medical Products Administration [4] - Future coverage of Paigebin is anticipated to rise as more research supports its efficacy [5] Group 4: Communication and Disclosure - The company ensured that all communications during the performance briefing were conducted in accordance with its information disclosure management system [5] - No undisclosed significant information was leaked during the investor relations activity [5]

厦门特宝生物工程股份有限公司 2023 年年度股东大会 会议资料 （688278） 中国·厦门 厦门特宝生物工程股份有限公司 2023 年年度股东大会会议资料 会议须知 为保障厦门特宝生物工程股份有限公司（以下简称"公司"）全体股东的 合法权益，维护股东大会的正常秩序，确保本次股东大会顺利召开，根据《公 司章程》《股东大会议事规则》及有关法律法规的规定，特制定本须知，望出 席股东大会的全体人员遵照执行。 六、股东及股东代理人要求在股东大会现场会议发言的，可在签到时先向 大会会务组登记，由大会统筹安排发言。每位股东发言时应先报告所持股份数 和持股人名称，发言主题应与本次会议议题相关，且简明扼要地阐述观点和建 议。 七、股东及股东代理人要求发言时，不得打断会议报告人的报告或其他股 东及股东代理人的发言。股东及股东代理人违反上述规定，会议主持人有权加 以拒绝或制止。 八、主持人可安排公司董事、监事、高级管理人员回答股东所提问题。但 与本次股东大会议题无关或涉及公司商业秘密的问题，公司有权不予回应。 九、为提高大会议事效率，在回复股东问题结束后，股东及股东代理人即 进行表决。议案表决开始后，大会将不再安排股东发言。 ...

国金证券股份有限公司 关于厦门特宝生物工程股份有限公司 2023年度持续督导跟踪报告 国金证券股份有限公司（以下简称"保荐机构"）作为厦门特宝生物工程股 份有限公司（以下简称"特宝生物"或"公司"）首次公开发行股票并在科创板 上市项目的保荐机构，根据《中华人民共和国证券法》《证券发行上市保荐业务 管理办法》《上海证券交易所科创板股票上市规则》《上海证券交易所上市公司自 律监管指引第11号——持续督导》等相关规定，负责特宝生物上市后的持续督导 工作，并出具2023年度持续督导跟踪报告。 | 工作内容 | 序号 | | 持续督导情况 | | --- | --- | --- | --- | | 建立健全并有效执行持续督导工作制度，并针 | 1 | | 保荐机构已建立并有效执行了持续 督导制度，并制定了相应的工作计 | | 对具体的持续督导工作制定相应的工作计划 | | | | | | | | 划 | | 根据中国证监会相关规定，在持续督导工作开 | 2 | | 保荐机构已与特宝生物签订《持续 | | 始前，与上市公司或相关当事人签署持续督导 | | | 督导协议》，该协议明确了双方在持 | | 协议，明确双方在持续 ...

本次高新技术企业认定系公司原证书有效期满后进行的重新认定。根据高新技 术企业认定管理办法及国家相关税收政策规定，公司自通过高新技术企业认定起连 续三年可享受国家税收优惠政策，即按 15%的税率缴纳企业所得税。该事项不影响 公司目前适用的企业所得税税收优惠政策，不会对公司经营业绩产生重大影响。 特此公告。 厦门特宝生物工程股份有限公司 董事会 2024 年 4 月 16 日 证券代码：688278 证券简称：特宝生物 公告编号：2024-016 厦门特宝生物工程股份有限公司 关于通过高新技术企业认定的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 厦门特宝生物工程股份有限公司（以下简称"公司"）于近日收到由厦门市科 学技术局、厦门市财政局、国家税务总局厦门市税务局联合颁发的《高新技术企业 证书》（证书编号为：GR202335100220），发证时间为 2023 年 11 月 22 日，证书 有效期为三年。 ...

Investment Rating - The investment rating for the company is "Outperform the Market" [2][7] Core Views - The company, TeBao Bio, has experienced rapid revenue growth driven by the continuous increase in sales of its core product, Pegasys, which generated revenue of 1.79 billion yuan in 2023, accounting for 85% of total revenue [5][6] - The company's net profit for 2023 reached 555 million yuan, reflecting a year-on-year increase of 93.5%, with a net profit margin of 26.5% [6][14] - The market for chronic hepatitis B treatment is expanding, with Pegasys being the only long-acting interferon drug available in China, indicating significant growth potential [6][9] Summary by Sections Financial Performance - In 2023, the company achieved an operating revenue of 2.1 billion yuan, a 37.6% increase from the previous year [8][14] - The gross profit margin improved to 93.3%, primarily due to the expiration of patent fees related to a partnership with JianKai Technology [6][14] - The company forecasts net profits of 751 million yuan, 1.05 billion yuan, and 1.44 billion yuan for 2024, 2025, and 2026, respectively [7][14] Product Pipeline - Pegasys is projected to continue its growth, with expected revenue increases of 38% annually from 2024 to 2026 [9][10] - Other long-acting recombinant protein products, including long-acting G-CSF and growth hormone, are entering the market, contributing to a second growth curve for the company [6][10] - The long-acting EPO product is expected to launch in 2025, with initial revenue projections of 20 million yuan [11][12] Market Position - The penetration rate of Pegasys among eligible chronic hepatitis B patients is currently only 6-10%, indicating substantial room for growth [9][10] - The company is well-positioned to benefit from favorable policies and industry trends aimed at increasing hepatitis B diagnosis and treatment rates in China [6][9]